127 related articles for article (PubMed ID: 29577875)
21. The N-terminal end of the CH2 domain of chimeric human IgG1 anti-HLA-DR is necessary for C1q, Fc gamma RI and Fc gamma RIII binding.
Morgan A; Jones ND; Nesbitt AM; Chaplin L; Bodmer MW; Emtage JS
Immunology; 1995 Oct; 86(2):319-24. PubMed ID: 7490135
[TBL] [Abstract][Full Text] [Related]
22. Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1.
Hezareh M; Hessell AJ; Jensen RC; van de Winkel JG; Parren PW
J Virol; 2001 Dec; 75(24):12161-8. PubMed ID: 11711607
[TBL] [Abstract][Full Text] [Related]
23. Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc.
Idusogie EE; Presta LG; Gazzano-Santoro H; Totpal K; Wong PY; Ultsch M; Meng YG; Mulkerrin MG
J Immunol; 2000 Apr; 164(8):4178-84. PubMed ID: 10754313
[TBL] [Abstract][Full Text] [Related]
24. Group G streptococcal IgG binding molecules FOG and protein G have different impacts on opsonization by C1q.
Nitsche-Schmitz DP; Johansson HM; Sastalla I; Reissmann S; Frick IM; Chhatwal GS
J Biol Chem; 2007 Jun; 282(24):17530-6. PubMed ID: 17449474
[TBL] [Abstract][Full Text] [Related]
25. Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX.
Pawluczkowycz AW; Beurskens FJ; Beum PV; Lindorfer MA; van de Winkel JG; Parren PW; Taylor RP
J Immunol; 2009 Jul; 183(1):749-58. PubMed ID: 19535640
[TBL] [Abstract][Full Text] [Related]
26. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations.
Vafa O; Gilliland GL; Brezski RJ; Strake B; Wilkinson T; Lacy ER; Scallon B; Teplyakov A; Malia TJ; Strohl WR
Methods; 2014 Jan; 65(1):114-26. PubMed ID: 23872058
[TBL] [Abstract][Full Text] [Related]
27. Structural difference in the complement activation site of human IgG1 and IgG3.
Michaelsen TE; Sandlie I; Bratlie DB; Sandin RH; Ihle O
Scand J Immunol; 2009 Dec; 70(6):553-64. PubMed ID: 19906198
[TBL] [Abstract][Full Text] [Related]
28. Binding of complement subcomponent C1q to mouse IgG1, IgG2a and IgG2b: a novel C1q binding assay.
Leatherbarrow RJ; Dwek RA
Mol Immunol; 1984 Apr; 21(4):321-7. PubMed ID: 6610105
[TBL] [Abstract][Full Text] [Related]
29. Distribution of Anti-ABO Immunoglobulin G Subclass and C1q Antibody in ABO-incompatible Kidney Transplantation.
Lee KH; Won DI; Yook JM; Kim KY; Park SM; Park JH; Lee ES; Lim JH; Jung HY; Choi JY; Park SH; Kim CD; Kim YL; Kim HK; Huh S; Cho JH
Transplant Proc; 2018 May; 50(4):1063-1067. PubMed ID: 29731066
[TBL] [Abstract][Full Text] [Related]
30. Atomic resolution model of the antibody Fc interaction with the complement C1q component.
Schneider S; Zacharias M
Mol Immunol; 2012 May; 51(1):66-72. PubMed ID: 22425350
[TBL] [Abstract][Full Text] [Related]
31. Structural aspects of HLA class I epitopes reacting with human monoclonal antibodies in Ig-binding, C1q-binding and lymphocytotoxicity assays.
Duquesnoy RJ; Marrari M; Jelenik L; Zeevi A; Claas FH; Mulder A
Hum Immunol; 2013 Oct; 74(10):1271-9. PubMed ID: 23770250
[TBL] [Abstract][Full Text] [Related]
32. The different effector function capabilities of the seven equine IgG subclasses have implications for vaccine strategies.
Lewis MJ; Wagner B; Woof JM
Mol Immunol; 2008 Feb; 45(3):818-27. PubMed ID: 17669496
[TBL] [Abstract][Full Text] [Related]
33. C1q, a subunit of the first component of complement, enhances antibody-mediated apoptosis of cultured rat glomerular mesangial cells.
Sato T; van Dixhoorn MG; Heemskerk E; van Es LA; Daha MR
Clin Exp Immunol; 1997 Sep; 109(3):510-7. PubMed ID: 9328130
[TBL] [Abstract][Full Text] [Related]
34. Histidine-rich glycoprotein binds to human IgG and C1q and inhibits the formation of insoluble immune complexes.
Gorgani NN; Parish CR; Easterbrook Smith SB; Altin JG
Biochemistry; 1997 Jun; 36(22):6653-62. PubMed ID: 9184145
[TBL] [Abstract][Full Text] [Related]
35. Binding and complement activation by C-reactive protein via the collagen-like region of C1q and inhibition of these reactions by monoclonal antibodies to C-reactive protein and C1q.
Jiang HX; Siegel JN; Gewurz H
J Immunol; 1991 Apr; 146(7):2324-30. PubMed ID: 2005402
[TBL] [Abstract][Full Text] [Related]
36. Glycine 236 in the Lower Hinge Region of Human IgG1 Differentiates FcγR from Complement Effector Function.
Brinkhaus M; Douwes RGJ; Bentlage AEH; Temming AR; de Taeye SW; Tammes Buirs M; Gerritsen J; Mok JY; Brasser G; Ligthart PC; van Esch WJE; Verheesen P; de Haard H; Rispens T; Vidarsson G
J Immunol; 2020 Dec; 205(12):3456-3467. PubMed ID: 33188070
[TBL] [Abstract][Full Text] [Related]
37. Development of C1q Affinity Chromatography for the Study of C1q-IgG Interactions.
Marshall MJE; Knaupp A; Spick C; Koese I; Maier M; Cragg MS; Cymer F; Schlothauer T
J Immunol; 2023 Jun; 210(11):1837-1848. PubMed ID: 37093649
[TBL] [Abstract][Full Text] [Related]
38. Activation of the first component of human complement, C1, by monoclonal antibodies directed against different domains of subcomponent C1q.
Kilchherr E; Schumaker VN; Phillips ML; Curtiss LK
J Immunol; 1986 Jul; 137(1):255-62. PubMed ID: 3486914
[TBL] [Abstract][Full Text] [Related]
39. Immunoglobulin G antibody bound to the C1q subcomponent of human complement exhibits segmental flexibility.
Hanson DC; Schumaker VN
J Mol Biol; 1985 Jun; 183(3):377-83. PubMed ID: 3874967
[TBL] [Abstract][Full Text] [Related]
40. IgG pair formation on one antigenic molecule is the main mechanism of synergy between antibodies in complement-mediated lysis.
Hughes-Jones NC; Gorick BD; Miller NG; Howard JC
Eur J Immunol; 1984 Nov; 14(11):974-8. PubMed ID: 6209148
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
